News

The U.S. Food and Drug Administration (FDA) approved the use of Stivarga (regorafinib) for the treatment of patients with hepatocellular carcinoma (HCC), a form of…

Radiation-delivering microspheres developed by Sirtex are as effective as Nexavar (sorafenib) chemotherapy against a liver cancer known as hepatocellular carcinoma (HCC), according to a Phase 3…

A child exposed to a mother’s high-fat diet while in the womb and breastfeeding is at greater risk of developing non-alcoholic fatty liver disease (NAFLD)…

Transplanting fecal bacteria from a healthy person to someone who has a liver-connected brain impairment may be an effective way to treat the condition, known…

Candidate drug EDP-305 reduced fibrosis progression and improved non-alcoholic fatty liver disease (NAFLD) and primary biliary cholangitis (PBC) disease settings in several preclinical animal models, says…

NV556 inhibited tumor growth in mice with a liver disease known as non-alcoholic steatohepatitis, or NASH, according to a study by its maker, NeuroVive Pharmaceutical AB.

Cerenis Therapeutics has initiated a Phase 1 clinical trial of CER-209 for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

The latest preclinical results of Ocera Therapeutics’ ammonia scavenger OCR-002 showed that it can reduce fibrosis progression in animal models of non-alcoholic fatty liver…

Boston-based Albireo Pharma hosted an April 13 breakfast presentation in New York that featured an overview of the company’s clinical programs as well as a talk by…

Galectin Therapeutics’s lead drug GR-MD-02 may be a promising therapeutic approach to treat fibrosis in fatty liver disease — or non-alcoholic steatohepatitis (NASH) — based on results from…